"Say Hy" icon.

Say Hy to proven relapse prevention as a maintenance therapy in adults

Proven relapse prevention in a maintenance setting

ADVANCE-1 was a phase 3 multicenter, placebo-controlled, study to evaluate the efficacy, safety and tolerability of HyQvia as a maintenance therapy to prevent relapse in CIDP.1

Key inclusion criteria

  • 18 years of age1
  • Definite/probable CIDP1
  • Responded to previous IgG treatment (PR or CR of neurological symptoms and deficits)1
  • Receiving stable doses of IVIG dose range equivalent to a cumulative monthly dose of 0.4–2.4 g/kg BW for 12 weeks prior to screening1
  • INCAT disability score of 0–7 (inclusive)2

Key inclusion criteria

  • Patients with focal atypical or pure sensory atypical CIDP3
Chart of HYQVIA CIDP efficacy study design.

Primary endpoint: Proportion of patients who experienced a relapse, defined as an increase of 1 point relative to the pre-SC treatment baseline score in 2 consecutive adjusted INCAT disability scores obtained <7 days apart.1

Chart of HYQVIA CIDP efficacy treatment difference.
  • Median duration of exposure was 5.3 months in the HyQvia group and 4.7 months in the placebo group.1 Subjects received treatments for 6 months or until relapse/discontinuation.

BW=body weight; CI=confidence interval; CIDP=chronic inflammatory demyelinating polyneuropathy; CMAP=compound muscle action potential; CR=complete response; EFNS/PNS=European Federation of Neurological Societies/Peripheral Nerve Society; IgG=immunoglobulin G; INCAT=Inflammatory Neuropathy Cause and Treatment; IVIG=intravenous immune globulin; LLN=lower limit of normal; PR=partial response; rHuPH20=Recombinant Human Hyaluronidase; SC=subcutaneous; ULN=upper limit of normal.

Primary efficacy analyses were conducted in the modified intention-to-treat set (all randomized patients who received any double-blind medication) and compared relapse rates using a continuity-corrected χ2 test conducted at the 5% level of statistical significance.

Time to relapse by treatment group in ADVANCE-1* (secondary endpoint)

  • The Kaplan–Meier curves demonstrated early separation at ~Week 41
  • ADVANCE 1 was not designed to control for multiplicity, therefore no definitive conclusions may be drawn from this information.

*ADVANCE-1 was a Phase III, prospective, randomized, double-blind, multicenter, placebo-controlled study in which adults with CIDP on a stable dose of IVIG for 12 weeks before screening were randomized to be switched to HyQvia (n=62) or placebo (n=70). Median duration of exposure was 5.3 months in the HyQvia group and 4.7 months in the placebo group.1

INCAT score

The INCAT comprises two parts, the arm score and the leg score. Based on a patient’s level of impairment in their arms and legs, each part is scored between 0 and 5 points, resulting in an INCAT total score between 0 and 10. Note: INCAT score is inversely related to function, with 0 representing no functional impairment and 10 representing inability to make any purposeful movement with either arms or legs.2

Definite/probable CIDP definitions4*

Definite: at least one of the following

(a) Motor distal latency prolongation 50% above ULN in two nerves (excluding median neuropathy at the wrist from carpal tunnel syndrome), or

(b) Reduction of motor conduction velocity 30% below LLN in two nerves, or

(c) Prolongation of F-wave latency 30% above ULN in two nerves (50% if amplitude of distal negative peak CMAP <80% of LLN values), or

(d) Absence of F-waves in two nerves if these nerves have distal negative peak CMAP amplitudes 20% of LLN + 1 other demyelinating parameter in 1 other nerve, or

(e) Partial motor conduction block: 50% amplitude reduction of the proximal negative peak CMAP relative to distal, if distal negative peak CMAP 20% of LLN, in two nerves, or in one nerve + 1 other demyelinating parameter* in 1 other nerve, or

(f) Abnormal temporal dispersion (>30% duration increase between the proximal and distal negative peak CMAP) in 2 nerves, or

(g) Distal CMAP duration (interval between onset of the first negative peak and return to baseline of the last negative peak) increase in 1 nerve (median 6.6 ms, ulnar 6.7 ms, peroneal 7.6 ms, tibial 8.8 ms) + 1 other demyelinating parameter in 1 other nerve

Probable:

30% amplitude reduction of the proximal negative peak CMAP relative to distal, excluding the posterior tibial nerve, if distal negative peak CMAP 20% of LLN, in two nerves, or in one nerve + 1 other demyelinating parameter in 1 other nerve

Evaluating activities with HyQvia (secondary endpoint)

R-ODS analysis, least squares (LS) mean changes.1,2†

Chart of HYQVIA LS mean treatment difference.

ADVANCE-1 was not designed to control for multiplicity, therefore no definitive conclusions may be drawn from this information.

ANCOVA=analysis of covariance; LS=least squares; R-ODS=Rasch-built Overall Disability Scale; SE=standard error.

*ADVANCE-1 was a Phase III, prospective, randomized, double-blind, multicenter, placebo-controlled study in which adults with CIDP on a stable dose of IVIG for 12 weeks before screening were randomized to be switched to HyQvia (n=62) or placebo (n=70). Median duration of exposure was 5.3 months in the HyQvia group and 4.7 months in the placebo group. The analysis of the primary endpoint demonstrated a statistically significant difference between the relapse rates for HyQvia (14.0%) and placebo (32.3%); p=0.0314. Treatment difference of -18.3% (two-sided 95% CI: -32.1%,-3.1%).1

The R-ODS score, used to assess activities of daily living, was a centile metric score with lower scores reflecting more severe limitations. Change from pre-SC treatment baseline in R-ODS centile metric scores at the end of the study visit using ANCOVA.2

Review safety information

Review Important Safety Information, including contraindications and other specific warnings and precautions to consider when prescribing and monitoring patients treated with HyQvia.

Interim results of ADVANCE-3

ADVANCE-3: A phase 3b, single-arm, open-label, multicenter, extension study to assess the long-term safety, tolerability, and immunogenicity of HyQvia for maintenance therapy for CIDP. The study included subjects who completed ADVANCE-1 study without CIDP worsening or relapsing (n=79).1

Interim analysis of primary objectives: Long-term safety, tolerability and immunogenicity1. Exploratory objective of interest: CIDP relapse rate.5 Data included 79 patients with a range of follow-ups from 0 to 5.1 years and a total follow-up of 169 patient-years. A total of 2590 HyQvia infusions were administered.1

1.6% 6-month relapse rate.
8.8% interim study period relapse rate.

*ADVANCE-3 was initiated December 2016 and completed March 31, 2023 (last subject out). Interim analysis data freeze February 2022.

ADVANCE-3 study design: ADVANCE-3 was a Phase IIIb, single-arm, open-label, multicenter, extension study which assessed the long-term safety and tolerability of HyQvia for maintenance therapy for CIDP. At interim analysis, data included 79 patients with range of follow-ups from 0 to 5.1 years. The study was open to subjects who completed Study 1 without CIDP worsening or relapse. The dosing range was 0.4 g/kg to 2.4 g/kg, given in a frequency of 2-, 3- or 4-week intervals.2

Get answers to your questions. Talk to a representative about HyQvia.

References:
  1. HyQvia. Prescribing information. Takeda Pharmaceuticals U.S.A., Inc.; 2024.
  2. Bril V, et al. J Peripher Nerv Syst. 2023;28(3):436-449.
  3. Bril V, et al. J Peripher Nerv Syst. 2023;28(3):436-449. Supplementary appendix.
  4. Van den Bergh PYK, et al. Eur J Neurol. 2010;17(3):356–363.
  5. Hadden RD, et al. EAN 2023, July 1–4 2023, poster presentation.